REMAP-CAP (MACROLIDE)

Research Question

Does one of several investigational therapies improve all-cause mortality in adult patients admitted to the ICU for severe community-acquired pneumonia who are undergoing organ support?

Patient Type

COVID

INTERVENTION Type

Pharmacologic

GROUP A

Azithro 3 to 5 days

GROUP B

Azithro 14 days

INCLUSION CRITERIA

  1. Patients are only eligible for this domain if they have received a beta-lactam + macrolide intervention in the antibiotic domain.

​

INCLUSION TIME LIMIT

-

EXCLUSION CRITERIA

  1. Agreement to participate in this domain was declined or not sought before the end of Day 5.
  2. Microbiological confirmation strongly suspects Legionella or any other form of atypical pneumonia by the clinician.
  3. Macrolide antibiotics have already been discontinued for >36 hours.
  4. The treating physician believes involvement in the domain would not be in the best interest of the patient.

​

Does your patient meet this criteria?

Call your research coordinator #20064 - #20065 - #20093

Recherche | SI CHUM

Une équipe passionnée - au service des patients et du savoir

ÉTUDES
Liste complète
ÉQUIPE
ChercheursSoutien
AUTRES
Contactez nousCCCTG
© 2022-2023 CHUM